Table 2.
Clinical outcomes between MSD group and HID group.
| Variable | MSD group (103) | HID group (91) | p value |
|---|---|---|---|
| Primary GF, n (%) | 4/103 (3.9) | 2/91 (2.2) | 0.686 |
| Patients survived for more than 28 days, n (%) | 98/103 (95.1) | 88/91 (96.7) | 0.725 |
| Incidence of engraftment, n (%) | |||
| Incidence of myeloid engraftment | 98 /98 (100) | 87/88 (98.9) | 0.469 |
| Incidence of platelet engraftment | 95/98 (96.9) | 87/88 (98.9) | 0.624 |
| Neutrophil engraftment, days, median (range) | 13 (8–24) | 12 (8–21) | 0.107 |
| Platelet engraftment, days, median (range) | 17 (7–41) | 16 (8–154) | 0.643 |
| Late GF and PGF, n (%) | |||
| Late GF | 5/98 (5.1) | 3/88 (3.4) | 0.724 |
| PGF | 9/98 (9.2) | 7/88 (7.9) | 0.401 |
| Acute GvHD | 10/98 (10.2) | 46/88 (52.3) | 0.000* |
| Grade II–IV, n (%) | 5/98 (5.1) | 25/88 (28.4) | 0.000* |
| Grade III–IV, n (%) | 0/98 (0) | 10/88 (11.4) | 0.001* |
| Patients survived longer than 100 days, n (%) | 92/98 (93.9) | 82/88 (96.6) | 1.000 |
| Chronic GvHD | 5/92 (5.4) | 22/82 (26.8) | 0.000* |
| Extensive cGvHD | 1/92 (1.1) | 5/82 (6.1) | 0.052 |
| Viremia | |||
| CMV | 43/103 (41.7) | 48/91 (52.7) | 0.150 |
| EBV | 26/103 (25.2) | 26/91 (28.6) | 0.629 |
| EBV-associated PTLD | 4/103 (3.9) | 5/91 (5.5) | 0.423 |
| Overall survival, n (%) | 86/103 (83.5) | 72/91 (79.1) | 0.397 |
| ⩽20 years | 22/24 (91.7) | 42/51 (82.4) | 0.272 |
| 20–40 years | 51/62 (82.3) | 25/33 (75.8) | 0.472 |
| ⩾40 years | 14/17 (82.4) | 5/7 (71.4) | 0.487 |
CMV, cytomegalovirus; EBV, Epstein–Barr virus; GF, graft failure; GvHD, graft versus host disease; HID, haplo-identical donor; MSD, matched sibling donor; PGF, poor graft function; PTLD, post-transplant lymphoproliferative disorders.
*
statistical difference (P<0.05).